Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related mortality in the US within the next decade[1]. Surgical resection significantly improves prognosis, especially in early stage disease, with stage 1A PDAC patients achieving an 80 % 5-year survival rate [2–4]. Therefore, early detection of small asymptomatic PDAC or precursor lesions may improve overall survival [5,6]. While there is no population screening for pancreatic cancer, it is recomm…